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Abstract
 .The human transferrin receptor hTfR has been used as a model molecular target to direct therapeutic agents to tumor
cells and to shuttle drugs across the blood–brain-barrier. We show in the current study that receptor expression and
regulation can be visualized by NMR imaging, when the receptor is probed with a sterically protected iron containing
magnetic hTfR probe. We were able to demonstrate that the novel receptor probe was an iron source that could enter the
cells via the hTfR but did not play an immediate role in iron downregulation of hTfR within incubation times tested. Using
genetically engineered rat 9L gliosarcoma cell lines with three different forms of the hTfR, we also demonstrated that
receptor expression and regulation can be visualized by NMR imaging using the probe. This research provides proof of the
principle that it is possible to image receptor gene expression and regulation and it demonstrates that it may be possible to
image gene transfer in vivo. q 1998 Elsevier Science B.V.
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1. Introduction
Many studies have explored the human transferrin
 .receptor hTfR as a possible molecular model for
attempting tumor-specific targeting of therapeutic
agents. The transferrin receptor has also received
considerable attention recently as a potential
chemotherapeuticrgene therapeutic target because of:
 . w x  .1 its overexpression in many tumors 1,2 , 2 its
 .potential use for tumor detection, and 3 its potential
w xuse to detect gene expression by NMR imaging 3 .
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The hTfR is a homodimer transmembrane glyco-
protein with an overall molecular weight of approxi-
 .mately 180 kDa. Transferrin receptors TfRs are
present in almost all mammalian cells and are respon-
sible for cellular acquisition of iron from transferrin
 .Tf by receptor-mediated endocytosis. The intact
receptor is generally regulated by two major factors,
cellular iron status and cell growth. The synthesis of
 .the receptor and therefore, cellular iron levels is
mainly controlled through an iron-dependent negative
feedback in cells. Recent studies have shed light on
the molecular basis by which iron regulates transfer-
w x Xrin receptor expression 4–9 . The 3 untranslated
region of mRNA encoding the transferrin receptor
contains five cis-acting RNA iron-regulatory ele-
 .ments IREs and an RNA instability motif. The
0167-4889r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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IREs, under low iron-level conditions, are bound by
 .an IRE-binding protein IRP . The high-affinity inter-
action between IRP and IRE inactivates the instabil-
ity element leading to repression of mRNA degrada-
tion, higher TfR mRNA levels, and ultimately, higher
levels of the receptor protein. Under conditions of
high iron levels the reverse is true. When the cell
experiences high levels of iron a conformational
change takes place in the IRP. This change decreases
the affinity of the IRP for IREs and binding does not
occur. The RNA instability domain is exposed and
TfR mRNA is degraded resulting in lower levels of
TfR protein.
Some investigators have suggested that receptor
overexpression may lead to iron accumulation in cells
w xpotentially detectable by imaging 3 . It has also been
recognized that because intracellular iron homeostasis
is maintained by a well developed control mecha-
nism, addition of iron to cell culture or an animal
model can only finitely increase the iron level within
the cell. The reason for this is that increases in
cellular iron also downregulate TfR levels, decreasing
its own uptake. We reasoned that it would be possible
to circumvent the iron-mediated regulatory response
by ‘masking’ internalized iron via conjugation to a
dextran-coated monocrystalline iron oxide nanoparti-
 . cle MION with subsequent modification to Tf Tf–
.MION . Since these complexes do not immediately
release iron, we hypothesized that the internalized
complexes should not immediately affect iron home-
ostasis and, because of their superparamagnetism,
w xamplify the NMR signal emanating from cells 10 .
In the current study, we genetically engineered 9L
gliosarcoma cell lines stably expressing three differ-
ent forms of hTfR. Clone 1.6 expressed a version of
the receptor that overexpresses an iron-regulatable
form of the hTfR mRNA. Clone 3.9 expressed a
version of the hTfR which lacked mRNA destabiliza-
tion motifs and therefore constitutively overexpressed
high levels of hTfR protein. Clone 4.2 expressed a
version of the receptor whose mRNA was constitu-
tively unstable and therefore expressed low levels of
the receptor. Using these cell lines, we were able to
demonstrate that Tf–MION was an iron source that
could enter the cells via the hTfR but did not play an
immediate regulatory role in hTfR expression. In
addition, we were able to demonstrate that cells
expressing high levels of the transfected hTfR pro-
duced significant signal intensity changes on MRI
images when compared to cells expressing little or no
hTfR.
2. Materials and methods
2.1. Cells
Rat 9L gliosarcoma cells Brain Tumor Research
.  .Center, San Francisco, CA 15 were grown in Dul-
becco’s modified Eagle’s medium DMEM, Cellgro,
.Mediatech, Washington, DC containing 10% fetal
 .bovine serum FBS, Cellgro with medium changes
every 3 days. Transfected cells were grown and
maintained under the same condition.
2.2. Plasmid constructs and stable transfection
Plasmids containing cDNA for each of the hTfR
 .mutants TRS-1, TRS-3, and TRS-4 were a generous
gift of Dr. Joe Hardford, Dr. Richard Klausner, and
 .Dr. Tracey Rouault NICHD, NIH, Bethesda, MD .
The construction of these plasmids have been de-
w xscribed elsewhere 4,5 . The G418 resistance expres-
sion plasmid contains a neomycin phosphotransferase
cDNA under control of the Rous sarcoma virus pro-
moter. To generate cells stably expressing the differ-
ent forms of the hTfR, 9L cells were transfected with
the different plasmids as follows. Cells were plated in
p100 dishes and used when they achieved 60–70%
confluence. For each p100 dish, a mixture of 10–20
mg of plasmid DNA 10:1 mixture of TRS plasmid to
. G418 plasmid in 2= transfection buffer 1=TBs
100 mM HEPES, 560 mM NaCl, 3 mM Na HPO ,2 4
.pH 7.1, autoclaved was prepared by combining equal
volumes of DNA in water and 4=TB. The mixture
was added dropwise to 500 ml of 0.25 M CaCl and2
allowed to incubate at room temperature for 30 min.
Following incubation, the mixture was added to cells
which had previously been washed once with Hanks
 .balanced salt solution HBSS, Cellgro . After 30 min
incubation, fresh media was added to the cells with-
out removal of the precipitate. After 5 h the media
was removed, the cells were washed, and 1 ml of
 .GSS 1=TB, 15% glycerol was added for 2 min at
378C. Following removal of the GSS the cells were
( )A. Moore et al.rBiochimica et Biophysica Acta 1402 1998 239–249 241
washed and refed with replete medium. After 48 h
 .the cells were selected in G418 1 mgrml until
single colonies could be isolated and expanded. Sta-
bly transfected cells were maintained in the absence
of G418 but were periodically passaged in G418-con-
taining medium to assure integrity of the plasmid
expression.
2.3. Synthesis of receptor ligands
The hTfR receptor expression in cell lines was
tested using different ligands including radiolabeled
human holotransferrin, a superparamagnetic
 .monocrystalline iron oxide nanoparticle MION sur-
 .face modified with holo Tf Tf–MION andror con-
trol ligands consisting of MION or MION conjugated
 .to human serum albumin HSA–MION . Tf, HSA,
 .both from Sigma, St. Louis, MO and MION were
radiolabeled with Na125I in 0.05 M sodium carbonate,
pH 8.7 in the presence of IodoGen Pierce, Rockford,
.IL . All three compounds were purified after iodina-
tion by gel filtration through Sephadex G-25 columns.
Dextran-coated MION was synthesized as de-
w xscribed in more detail elsewhere 10,11 . MION parti-
cles were purified by dialysis against acetate buffer
0.01 M sodium acetate, 0.15 M sodium chloride, pH
.6 and stored at 48C for further use . MION has
previously been shown to consist of a central
monocrystalline crystal core volume weighted crys-
.tal size 3.94"0.32 nm to which are attached multi-
ple dextran molecules. These dextran molecules shield
the iron oxide surface and increase the hydrodynamic
radius of the agent to 17.1"0.9 nm volume weighted
.size by laser light scattering . The dextranrFe wrw
ratio is 1.6:1. R relaxivitys12.5 mM sy1, R1 2
relaxivity s 45.1 mM sy1. Magnetization is 68
emurg Fe at 1.5 T. MION elutes as a single narrow
peak by high-performance liquid chromatography
with a dispersion index of 1.034; the median MION
particle diameter thus corresponds in size to a protein
with a mass of 775 kDa and contains an average of
w x2064 iron atoms 10 . This number was used to
convert cellular MION uptake into iron uptake in the
experiments described below.
MION modification with proteins was carried out
by partial oxidation of dextran, protein binding and
subsequent reduction of Schiff’s bases. MION was
initially oxidized with sodium periodate 1 mg
.NaIO r1 mg Fe for 40 min in the dark, dialyzed4
against sodium bicarbonate buffer 0.02 M sodium
.bicarbonate, 0.15 M sodium chloride, pH 8.7 for 1 h
and then against 0.15 M sodium chloride for another
hour. Radiolabeled holo Tf or HSA were added to
oxidized MION and incubated for 3 h at room tem-
perature. Sodium cyanoborohydrate was then added
at 1 mgrml and conjugates were left overnight at
48C. Conjugates were purified on a BioGel 1.5A
 .column Bio-Rad, Richmond, CA . Tf–MION con-
tained 0.22 mg of holo Tfrmg Fe and HSA–MION
contained 0.24 mg of HSArmg Fe. Laser light scat-
tering showed a size of 39.6"1.3 nm for Tf–MION
and 37.3"0.4 nm for HSA–MION. The specific
activities were 17.9 cpmrng of protein for Tf–MION,
15.1 cpmrng of protein for HSA–MION, and 10
cmprng of Fe for MION.
2.4. Fluorescence microscopy
Fluorescence microscopy was used to confirm the
presencerabsence of hTfR expression in the different
subclones. Cells were plated on 12-mm microscope
 .cover glasses Fisher Scientific, Pittsburgh, PA
placed in 12 well plates Falcon, Becton Dickinson,
.Lincoln Park, NJ 24 h before the experiment. On the
day of the experiment, cells were fixed with 2%
formaldehyde, rinsed with PBS 0.01 M phosphate
.buffer, 0.15 M sodium chloride pH 7.4 with 10%
 .horse serum Cellgro and incubated for 45 min with
a mouse monoclonal anti-hTfR antibody clone
.B3r25, Boehringer Mannheim, Indianapolis, IN in
incubation buffer PBS with 10% horse serum and
 .0.2% saponin Sigma . Following incubation, cells
were rinsed with the same buffer and incubated with
FITC-labeled goat anti-mouse antibody Southern
.Biotechnology Associates, Birmingham, AL diluted
 .1:200 in incubation buffer. After three washes,
cover slips were mounted on the microscopy slides
 . Fisher Scientific using Fluoromount-G Southern
.Biotechnology Associates . Cells were examined with
an inverted fluorescence microscope Zeiss Axiovert
.100TV, Wetzlar, Germany equipped with an FITC
 .filter set Omega Optical, Brattleboro, VT , an inten-
 .sified CCD video camera Photometrics, Tuscon, AZ
connected to a Power Macintosh 7600r120 com-
puter.
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2.5. Quantitati˝e cell-uptake assays
Comparative uptake measurements were per-
formed in different clones using a simple binding
 5 .assay. Cells 10 cellsrwell in culture medium were
 .plated onto 24-well plates Falcon 24 h before the
experiment. 125I labeled Tf, Tf–MION, HSA–MION,
or MION were added to the cells at various concen-
 .trations see Figs. 1–5 and incubated at 378C for 1 h.
Cells were then washed three times with HBSS and
lysed in 0.5 ml 1% Triton X-100, 1 mM EDTA, pH 8
prior to radioactivityrprotein determinations. Cell-as-
sociated radioactivity was counted in a gamma-coun-
 .ter 1282 Compugamma CS, LKB Wallac, Sweden .
All experiments were performed in duplicate.
To determine whether expression of the hTfR could
be upregulated as postulated, cells from the 1.6 sub-
clone were treated with 100 mM deferoxamine mesy-
 .late Sigma for 16 h. Upregulated 1.6 cells were then
incubated with either iron ammonium citrate Fe: 100
.  .mgrml , Tf–MION Fe: 100 mgrml , or in cell
 .culture medium Fe: 0.1 mgrml . At different time
points following this incubation, TfR expression was
probed for with 125I-Tf as described above. Experi-
mental conditions for this experiment were identical
as described above. Nontreated cells served as a
control.
A competition assay was utilized to determine
whether Tf–MION uptake into cells would be in-
hibitable by Tf or by MION. These studies were
 5carried out with cells of the 3.9 clone. Cells 10
.cellsrwell in culture medium were plated onto 24-
well plates 24 h before the experiment. Unlabeled Tf
 . from 2 to 200 mgrwell and MION 10 to 500 mg
.Ferwell were added to the cells immediately prior
 .to the addition of iodinated Tf–MION 25 mgrwell .
Incubation, washing and counting were identical to
the procedure described above. All experiments were
performed in duplicate.
2.6. MR phantoms and imaging
Special phantoms were constructed for NMR
imaging that consisted of cells being embedded in
agar to prevent drying and susceptibility artifacts.
Two separate experiments were carried out. In the
first experiment the regulatable 1.6 clone was treated
with deferoxamine or not treated, followed by prob-
ing with either Tf–MION or MION alone, washed
extensively and then embedded in agarose prior to
imaging. In the second experiment either the 3.9
subclone or the 9L wild type were incubated with
 6 .Tf–MION or Tf alone. All cells 10 cellsrwell
 .were plated onto six-well plates Falcon . Tf, MION,
and Tf–MION were incubated for 1 h followed by
washing with HBSS three times, trypsinization and
centrifugation of cells. Each 24 wells of tissue-culture
plate was then covered with 1.5 ml of 1% agarose in
 .water Bio-Rad, Hercules, CA . Cell pellets were
resuspended in 30 ml of warm agarose and placed
into holes previously stencilled into the agarose. Each
well was then sealed with an additional 0.5 ml of
agarose.
NMR imaging was performed with a 1.5-T super-
conducting magnet Signa 5.0; GE Medical Systems,
.Milwaukee, WI using a 5-in. surface coil. The imag-
ing protocol consisted of coronal T1 weighted spin
 .  .echo SE 300r12 or T2 weighted SE SE 3000r100
sequences. Slice thickness was 3 mm. The field of
 . 2view FOV was 10 or 12 cm , using a 256=256
imaging matrix and 2–4 acquisition averages. Signal
 .intensity SI measurements were obtained in regions
 .of interest ROI from experimental cell pellets as
well as agarose.
3. Results
3.1. Characterization of subclones
Approximately 10–15 G418-resistant clones were
isolated for each receptor expression plasmid. To
confirm the expression of hTfR by these cells, we
initially observed the relative hTfR expression by
immunofluoresence. The subclones were fixed, incu-
bated with anti-hTfR antibodies, and viewed by fluo-
 .rescence microscopy Fig. 1 . Cells derived from
transfection of the TRS-3 plasmid expresses consti-
.tutive high levels of hTfR showed increased levels
of fluorescence relative to mock transfected and no
antibody controls. Clone 3.9 was chosen for further
studies because it was the highest expressing clone
and showed extensive accumulation of the fluo-
rochrome both bound to the cell surface as well as
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Fig. 1. Fluorescence micrograph. Fluorescence microscopy of the different 9L transfected clones using mouse anti-hTfR antibody and FITC labeled goat anti-mouse
antibody: upper left: 3.9 clone expressing a version of the hTfR which lacks mRNA destabilization motifs and therefore constitutively overexpresses hTfR; upper right 1.6
clone expressing a version of the receptor that expresses an iron-regulatable form of the hTfR mRNA; lower left: 4.2 clone expressing a version of the receptor whose
mRNA was constitutively unstable and therefore expressed low levels of the receptor; lower right: nontransfected wild type.
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Fig. 2. Binding and internalization of 125I-labelled human holo-
transferrin into the different genetically engineered cell lines
 5 .incubation time 60 min; 10 cellsrwell; 378C .
internalized into small vesicles. The intracellular dis-
tribution of the fluorochrome was similar to that
observed in prior studies and represents hTfR in the
endosomal compartment. Cells derived from transfec-
tion with the regulatable form of the hTfR expression
 .TRS-1 plasmid appeared morphologically similar to
clone 3.9 but cells showed slightly lower overall
fluorescence; clone 1.6 was chosen from this trans-
fection for further study. Cells isolated from the
transfection with the TRS-4 expression plasmid
showed very weak levels of fluorescence consistent
with constitutive under expression of hTfR in these
cells. Clone 4.2 was chosen for further studies. Non-
 .transfected 9L wildtype WT cells showed very weak
levels of fluorescence.
3.2. Transferrin uptake
To confirm and quantify fluorescence microscopy
results, the level of hTfR expression of each clone
was measured by a radiolabeled ligand binding assay.
TRS-1.6, -3.9, -4.2, and WT cells were incubated
125 with I-labeled human Tf 1 mg to 75 mg of Tf
5 .added per 10 cells; Fig. 2 . Clone 3.9 with constitu-
tively overexpressed hTfR showed the highest Tf
 125uptake 0.56"0.09 pgrcell at the highest I-Tf
incubation corresponding to approximately 8.7=106
.iron moleculesrcell whereas uptake was lowest for
the WT cells devoid of the human receptor 0.13"
0.006 pgrcell corresponding to approximately 2.01
6 . =10 iron moleculesrcell . Clone 4.2 constitu-
.tively low expression of hTfR showed a slightly
higher uptake 0.18"0.04 pgrcell corresponding to
6 .approximately 2.8=10 iron moleculesrcell when
compared to WT cells. The regulatable 1.6 subclone
exhibited Tf uptake intermediate to clones 3.9 and
4.2 0.34"0.03 pgrcell corresponding to approxi-
6 .mately 5.3=10 iron moleculesrcell . These results
paralleled microscopy findings and confirm the ex-
pression of different levels of functional hTfR in the
transfected 9L cells.
3.3. Uptake of magnetic receptor probes into clones
To determine if the level of hTfR expressed was
predictive of magnetic Tf–MION uptake, clones were
incubated with 125I-labeled Tf–MION and cellular
 .uptake measured Fig. 3A . Clone 3.9 again exhibited
the highest Tf–MION uptake 1.54 " 0.005 pg
Fercell corresponding to approximately 1.68=1010
.Fe moleculesrcell , followed by the regulatable 1.6
subclone 0.87"0.001 pg Fercell corresponding to
9 .approximately 9.5=10 Fe moleculesrcell . The
lowest level of Tf–MION uptake was obtained with
clone 4.2. This level was similar to that measured for
control cells. The levels of Tf–MION uptake thus
paralleled the measured uptake of radiolabeled Tf
suggesting that hTfR levels are predictive of Tf–
MION uptake. To demonstrate that uptake of Tf–
MION was specific, it was measured in the absence
or presence of an excess of unlabeled Tf. Fig. 3B
shows that Tf–MION uptake into 3.9 cells can be
effectively inhibited by Tf decrease from 1.05"0.2
.pg Fercell to 0.27"0.07 pg Fercell but not by
 .MION Fig. 3B .
Since MION alone has also previously been shown
to be internalized into tumor cells by fluid-phase
w xpinocytosis 12 , additional uptake studies were per-
formed to rule out the possibility that significant
MION uptake was occurring via a nonreceptor medi-
 .ate pathway Fig. 3C . MION uptake was two to four
 .times lower range: 0.29–0.41 pg Fercell when
compared to the Tf–MION uptake range: 0.61–1.54
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 .Fig. 3. MION conjugate uptake. Different uptake experiments using the various genetically engineered 9L cell lines. A Tf–MION
 .  .uptake; B inhibition assay showing inhibition of Tf–MION uptake by Tf but not by MION in 3.9 cells; C nonconjugated MION
 .uptake into the different clones; D comparison of cellular uptake of Tf–MION and HSA–MION in 3.9 cells.
.pg Fercell in all cell lines tested. There was no
statistically significant difference in MION uptake
among the clones.
To test whether cell uptake would be mediated by
 .protein bound to MION rather than specifically Tf ,
additional uptake experiments were performed in 3.9
 .cells using HSA–MION or Tf–MION Fig. 3D .
HSA–MION uptake into 3.9 cells was considerably
 .lower 0.34"0.001 pg Fercell than Tf–MION up-
 .take 1.54"0.005 pg Fercell .
3.4. Receptor regulation
A potential problem of imaging intracellular para-
magnetic iron is its relative low abundance in the cell
and the fact that normal homeostatic mechanisms of
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Fig. 4. Uptake of 125I-labeled Tf in the regulatable 1.6 clone.
Prior to uptake studies, cells were upregulated by incubating for
 .16 h with deferoxamine upper three curves . Cells were then
 .incubated with either Tf–MION Fe: 100 mgrml , iron ammo-
 . nium citrate Fe: 100 mgrml or in culture medium Fe: 0.1
. 125mgrml , washed and then probed with I-Tf at the indicated
times.
Fig. 5. Regulation of Tf–MION uptake. Iron deprivation by
deferoxamine pretreatment leads to hTfR upregulation and in-
creased cellular internalization of the magnetic Tf–MION probe.
the cells downregulate the level of TfR and thereby
limit the ability to load cells with iron. Since several
studies have suggested that iron is not readily lost
w xfrom MION particles 10 , we determined if these
particles would allow cellular-iron acquisition with-
out receptor downregulation. Clone 1.6 cells were
treated with the iron chelator, deferoxamine, for 16 h
to upregulate TfR levels. The cells were then treated
with varying iron sources and the resulting TfR levels
were measured. As Fig. 4 shows, incubation with
iron rapidly decreases the level of TfR expressed by
the cells from 110"10 ng Tf bound to 45"2 ng Tf
.bound . Treatment of the cells with MION-Tf re-
sulted in little to no change in TfR levels compared
to 1.6 cells in culture medium. These results clearly
demonstrate that the iron contained in MION-Tf does
not immediately regulate the level of TfR in 1.6 cells.
Deferoxamine-induced hTfR upregulation in the
1.6 also resulted in higher Tf–MION uptake as shown
in Fig. 5. Cells incubated with deferoxamine for 16 h
showed a 2.6-fold higher Tf–MION uptake when
compared to 1.6 cells not treated with deferoxamine
 .2.27"0.15 pg Fercell vs. 0.87"0.001 pg Fercell .
To determine whether this hTfR regulation can be
visualized by NMR imaging, cell phantoms of the 1.6
clone were tested using the same experimental set up
Fig. 6. MR imaging of receptor regulation. MR imaging of hTfR
 .upregulated cells bright center embedded in agar phantom show
a lower MR signal intensity after probing with Tf–MION. Note
that MION alone does not change the signal intensity of the cell
pellet.
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 .deferoxamine treatment as described above. There
was clear evidence that differences in cellular Tf–
MION uptake were sufficient to alter the NMR signal
intensity in upregulated cells on either T2 weighted
 .  .Fig. 6 or T1 weighted images not shown . NMR
 .SIR cellragar signal intensity ratio in upregulated
cells and Tf–MION treated cells was 0.35 whereas it
was 0.54 in resting cells. There was no significant
difference in signal intensity changes with the MION
probe.
3.5. Effect of intracellular iron source on NMR signal
intensity
It has previously been suggested that holotransfer-
rin can deliver sufficient amounts of iron into cells to
change their magnetic properties and that this change
w xshould be detectable by imaging 3 . To investigate
this claim we utilized clone 3.9 no downregulation
.of constitutively overexpressed receptor and com-
pared the effect of Tf–MION or Tf probing by NMR
 .imaging Fig. 7 . In the case of Tf–MION, consider-
able differences in NMR signal intensity were on
either T2-weighted or T1-weighted MR images with
detection limits similar to those previously observed
w x  .10 Fig. 7 . T2-weighted images revealed the 3.9
clone to have significantly lower signal intensity than
Fig. 7. Similar NMR phantom as in Fig. 6; however, comparing
modulation of cellular signal intensity by either Tf or Tf–MION,
the WT clone does not express the hTfR. Dark-appearing central
cell pellets reflect Tf–MION uptake.
 .the WT SIR of 0.79 vs. 1.16, respectively . There
was no significant difference in NMR signal intensity
between 3.9 and WT clone incubated with Tf SIR of
.1.16 vs. 1.12, respectively . Treatment of WT cells
with Tf–MION resulted in only a minimal decrease
in signal intensity as predicted by the above quantita-
tive uptake studies.
4. Discussion
The current research represents the first direct
evidence that TfR receptor expression and regulation
can be visualized noninvasively by NMR imaging.
The method holds promise not only for high-resolu-
tion receptor mapping but also for in vivo imaging
and repeated sampling. More specifically the current
 .research shows that 1 Tf–MION can be internalized
 .into cells via the hTfR, 2 that receptor-mediated
 .endocytosis RME uptake of Tf–MION is specific,
 .regulatable and inhibitable, 3 that cellular accumu-
lation of iron from Tf–MION is more efficient for
NMR imaging when compared to iron from Tf, and
 .4 that internalized superparamagnetic Tf–MION is
sufficient to alter MR signal which allows visualiza-
tion of receptor gene expression and regulation.
4.1. Cellular iron uptake
In the current study we employed genetically engi-
neered 9L cell lines featuring constitutive overexpres-
 .sion of the hTfR clone 3.9 , constitutive low expres-
 .sion of the hTfR clone 4.2 or regulatable cells
 .  .clone 1.6 . Unmodified 9L wild type WT served as
control. Initial experiments confirmed different levels
of hTfR expression in the various clones as proven
by fluorescence microscopy and quantitative Tf bind-
ing studies. Our data also show that Tf-modified
MION particles are indeed internalized into tumor
cells with cellular uptake being highest in the clones
 .that constitutively overexpress clone 3.9 or have a
 .regulatable clone 1.6 and functional hTfR. In the
specific example of the 3.9 clone, iron uptake was as
high as 1.68=1010 Fe moleculesrcell for standard
incubation conditions, three orders of magnitude
 6higher than iron uptake via holo Tf 8.7=10 iron
.moleculesrcell; p - 0.001 . Similar observations
were also made in the case of the regulatable clone
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1.6 where iron uptake via Tf–MION was 9.5=109
iron moleculesrcell.
To confirm the specificity of hTfR-mediated Tf–
MION uptake, two separate experiments were con-
ducted. In the first set of experiments cellular uptake
of Tf–MION and HSA–MION were compared to
each other. Our results indicate that Tf–MION up-
take was approximately five times higher than
HSA–MION uptake, indicating that a receptor-medi-
ated pathway is responsible for the higher uptake.
Secondly, competitive uptake experiments showed
that cellular uptake of Tf–MION was inhibitable by
Tf but not by MION.
4.2. Cellular iron regulation
The hTfR tightly controls cellular iron homeostasis
w xby regulating cellular uptake of holo Tf 13 . Tf
enters cells by RME via coated pits resulting in
internalization into the endosomal system. Once in-
side the endosome, Tf associated iron is released low
.pH and the hTfR recycles back to the cell mem-
brane. Each hTfR is capable of internalizing two
molecules of Tf and the receptor cycle is typically 12
min assuring rapid and effective control of free intra-
cellular iron. Intracellular iron is stored in ferritin
where each molecule is capable of storing up to 4500
w xiron atoms 13 .
In the case of Tf–MION, we postulate that cellular
pathways are similar resulting in endosomal uptake
of particles. Experimental evidence that cellular
MION uptake occurs via the endosomal compartment
stems from previous correlative morphologic experi-
ments, competition assays, colocalization assays and
costaining for the lysosomal compartment with anti-
w xLGP-A antibody 14 . Although there exist no exact
figures of intracellular MION degradation rates, prior
research has shown that iron oxide particles are typi-
cally biodegraded within 7–14 days following incu-
bation and that fluorescently labeled MION becomes
nondetectable by fluorescence microscopy in cell cul-
w xture within 2–5 days 14 . The longevity of MION
particles in cells suggested to us that they might
constitute an iron source which does not immediately
contribute to the ‘regulatory iron pool’ hypothesized
to exist in cells. If the iron contained in MION could
circumvent this ‘pool’ or was delayed in its entry to
the pool, we reasoned that MION particles would be
a way to dramatically increase cellular iron uptake
without downregulating the uptake system, i.e., hTfR.
When we tested this idea the results were remarkable.
While iron dramatically lowered the level of TfR
MION-Tf particles had no effect on TfR levels rela-
tive to controls. These data validate the use of
MION-Tf as an in vivo tool to increase intracellular
iron levels and enhance imaging.
4.3. Effect of intracellular iron on NMR signal inten-
sity
Iron complexes can exhibit either paramagnetic or
superparamagnetic properties depending on the
molecular state of the iron. Iron in superparamagnetic
 .states as in MION has distinct effects on NMR
signal intensity and is detectable at much lower tissue
concentrations when compared to paramagnetic iron.
Although it has been postulated that genetic hTfR
expression should be detectable by NMR imaging of
w xparamagnetic iron delivered by Tf 3 our results did
not confirm this postulation. Conversely, our results
indicate that MION amplification results not only in
three orders of magnitude higher iron internalization
but also in one order of magnitude higher relaxivity
 .10 000-fold amplification . NMR imaging experi-
ments corroborated our hypothesis and showed that
this amplification is sufficient to alter NMR signal
using conventional imaging equipment and tech-
niques.
Internalized superparamagnetic MION complexes
uniquely changed NMR signal intensities as predicted
w xby theory 10 . On T2-weighted images internalized
iron decreased signal because of the high local MION
concentrations within endosomes forming strong lo-
cal susceptibility gradients. On T1-weighted images,
internalized iron increased signal intensity. Since
many cell types have been shown to internalize MION
w xby fluid phase endocytosis 10 , certain calculations
about the required receptor density can be made.
Assuming a threshold of detectable iron in 9L cells of
w xapproximately 2 ng Fe 10 this amount would be
achieved by fluid phase endocytosis alone in 105
cells distributed in a volume of 30 ml. Assuming
internalization of 1.54"0.005 pg Fercell of Tf–
MION in 3.9 cells, the detection threshold with cur-
rent clinical NMR techniques would theoretically be
roughly 103 cells incubated for 1 h. Conversely,
( )A. Moore et al.rBiochimica et Biophysica Acta 1402 1998 239–249 249
assuming a fixed cell population of 105r30 ml and a
receptor cycling time of 12 min it follows that a hTfR
receptor density 80 times lower than with the current
3.9 clone would still be sufficient to alter NMR
signal intensity. These calculations are based on spa-
tial resolutions of typical clinical imaging systems.
With the use of high field strengths and gradients,
resolution would be higher decreasing the threshold
w xof detectability 15 .
5. Conclusion
The current study shows that sterically protected,
magnetic Tf conjugates can be used for amplification
of receptor expression and that such cellular events
can be visualized by NMR imaging techniques. These
observations should be applicable to the study of
other receptor systems, both for their expression and
regulation. Furthermore, the method could be used to
probe for transgene expression potentially useful in
monitoring gene therapy.
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